What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak

BACKGROUND: Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease. METHODS: In this retrospective analysis of patients with COVID-19 admitted between March 2 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Monica, Purpura, Lawrence J., McConville, Thomas H., Neidell, Matthew J., Anderson, Michaela R., Bernstein, Elana J., Dietz, Donald E., Laracy, Justin, Gunaratne, Shauna H., Miller, Emily Happy, Cheng, Jennifer, Zucker, Jason, Shah, Shivang S., Chaudhuri, Shaoli, Gordillo, Christian A., Patel, Shreena R., Guo, Tai Wei, Karaaslan, Lara E., Reshef, Ran, Miko, Benjamin A., Bathon, Joan M., Pereira, Marcus R., Uhlemann, Anne-Catrin, Yin, Michael T., Sobieszczyk, Magdalena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031323/
https://www.ncbi.nlm.nih.gov/pubmed/33831046
http://dx.doi.org/10.1371/journal.pone.0249349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031323/
https://www.ncbi.nlm.nih.gov/pubmed/33831046
http://dx.doi.org/10.1371/journal.pone.0249349

Ejemplares similares